Kiran Mazumdar-Shaw explains how high private and public valuations provide the equity currency required to finance large corporate acquisitions.
Assertion Contradicted
Mazumdar-Shaw: Vijay Mallya has paid back everything he owed
“Well, he's paid back everything he owed. So I don't understand why he's still being targeted.”
Opinion
Mazumdar-Shaw: Biocon was the first startup in India
“Of course, a few years later, I was very lucky that I was able to get the brightest minds to join me, and I therefore consider myself really the first startup in the country.”
Prediction Not checkable as stated
Mazumdar-Shaw: Entering biosimilars now would severely hurt Indian pharma earnings
“If any Indian pharmaceutical company wants to now venture into biosimilars, like I have done, it will, you know, have a huge impact on their EBITDA and their earnings, which I don't think anyone wants to do at this point in time.”
Prediction Not checkable as stated
Mazumdar-Shaw: Regulations will permit CRISPR for genetic defects, not designer babies
“So I think they will allow you to use CRISPR technologies like they use gene therapies today. To basically correct genetic deficiencies, but not to choose the kind of baby you want, you know, like saying that, okay, I want my eyes, the eyes to be of this color…”
Insight
Mazumdar-Shaw: Going public creates valuation currency essential for scaling
“I believe that as you grow your company, you need you need a capital value for a kind of a currency that you use to grow your company with. So if you create a valuation for your company, you can use that as a very, very powerful currency to do many more things…”
Insight
Mazumdar-Shaw: People without children tend to be more philanthropic
“When you don't have kids, you tend to Be more philanthropic.”